Asahi Kasei Completes Acquisition of Veloxis Pharmaceuticals Inc.

Düsseldorf, March 17, 2020 – Asahi Kasei Corporation has completed its acquisition of US-based pharmaceutical company Veloxis Pharmaceuticals Inc. on March 3, 2020 (CET).

Veloxis Pharmaceuticals A/S, based in Denmark, has been established in June 2002 and is a specialty pharmaceutical company, which is focused on the development, manufacturing and sale of immunosuppressive drugs that are used during and after transplant surgery of organs. This includes ENVARSUS XR – an immunosuppressant developed to prevent organ rejection in people who have had a kidney transplant. The use of a proprietary drug delivery technology is a particular distinguishing feature of this drug. It serves to enhance oral bioavailability and control the release of the drug to improve efficacy and/or reduce side effects.

The acquisition of Veloxis Pharmaceuticals Inc. (hereafter ‘Veloxis’) – a wholly owned US-based subsidiary of Veloxis Pharmaceuticals A/S – provides Asahi Kasei with a business platform in the pharmaceutical industry of the USA. Asahi Kasei aims to achieve the following synergies through the acquisition:

a) Enhance licensing activity to obtain new pharmaceuticals as growth drivers by leveraging Asahi Kasei’s business platform in Japan and Asia together with Veloxis’ business platform in the U.S.

b) Discover and develop new pipeline opportunities that will meet high unmet medical needs by combining Asahi Kasei’s drug discovery capabilities and Veloxis’ expertise in the US market.

c) Accelerate the creation of new health care businesses by leveraging access to innovation and clinical practices in the U.S.

Asahi Kasei’s pharmaceuticals business provides a wide range of pharmaceuticals and diagnostic reagents. As a specialized, innovation-driven operation, the development of new world-class drugs is advanced to offer innovative and unique therapeutic solutions in the fields of orthopedics, critical/intensive care, urology, the immune system, and the central nervous system. Since the development of Japan’s first original antibiotic in 1954, Asahi Kasei has advanced the development of many innovative new drugs centering on these fields. In the medical sector, on the other hand, Asahi Kasei is one of the worldwide leading manufacturers of products for hemodialysis and therapeutic apheresis treatment.

Details of the Acquisition
On December 12, 2019, Asahi Kasei announced a tender offer for shares and warrants of Veloxis Pharmaceuticals A/S (listed on Nasdaq Copenhagen), headquartered in Copenhagen, Denmark, which owns 100 percent of Veloxis Pharmaceuticals Inc. The tender offer, which expired on January 14, 2020, was made by Asahi Kasei’s wholly owned Danish subsidiary in accordance with the Danish Takeover Order. All procedures related to this tender offer and required to make Veloxis Pharmaceuticals A/S a wholly owned subsidiary of Asahi Kasei were completed on March 3, 2020 (CET), whereby Veloxis Pharmaceuticals Inc. became a wholly owned, indirect subsidiary of Asahi Kasei. Veloxis Pharmaceuticals Inc. will continue to be managed by its current management team.

* * * * *

Publiziert durch

Veröffentlicht von:

Asahi Kasei Europe GmbH

Am Seestern 4
40547 Düsseldorf
Telefon: +49 (0)211 280 68 139

Sebastian Schmidt
Pressefach öffnen


Die Asahi Kasei Gruppe ist ein diversifizierter Konzern mit den Geschäftsbereichen Material, Homes und Healthcare, die unter dem Dach der operativen Holdinggesellschaft Asahi Kasei Corp. agieren. Asahi Kasei vermarktet seine innovativen Technologien und einzigartigen Werkstoffe weltweit. Mit mehr als 30 000 Mitarbeitern auf der ganzen Welt beliefert die Asahi Kasei Gruppe Kunden in mehr als 100 Ländern. "Creating for Tomorrow", diesem Unternehmensleitbild von Asahi Kasei folgen alle Geschäftsbereiche und arbeiten gemeinsam an einer lebenswerten Umwelt für Menschen weltweit.

Informationen sind erhältlich bei:

financial relations GmbH
Louisenstraße 97
61348 Bad Homburg
+49 (0) 6172 27159 12
291 Besucher, davon 1 Aufrufe heute